farnesyltransferase
Jump to navigation
Jump to search
Function
- transfers C-15 isoprenyl moiety via pyrophosphate
- prefers Met or Ser as X of CaaX motif
Structure
- heterodimer of an alpha & a beta subunit
Pharmacology
- farnesyltransferase inhibitor lonafarnib may delay mortality in patients with Hutchinson-Gilford syndrome[3]
More general terms
More specific terms
References
- ↑ Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell. 1990 Jul 13;62(1):81-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/2194674
- ↑ Seabra MC, Reiss Y, Casey PJ, Brown MS, Goldstein JL. Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell. 1991 May 3;65(3):429-34. PMID: https://www.ncbi.nlm.nih.gov/pubmed/2018975
- ↑ 3.0 3.1 Gordon LB, Shappell H, Massaro J et al Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018;319(16):1687-1695 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29710166 https://jamanetwork.com/journals/jama/fullarticle/2679278?
Hisama FM, Oshima J. Precision Medicine and Progress in the Treatment of Hutchinson-Gilford Progeria Syndrome. JAMA. 2018;319(16):1663-1664. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29710145 https://jamanetwork.com/journals/jama/fullarticle/2679255 - ↑ Gordon LB, Kleinman ME, Massaro J et al Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12;134(2):114-25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27400896 Free PMC Article